U.S. News: New form of levodopa might improve Parkinson's care
UC researcher presents trial results at national conference
Several national outlets, including U.S. News & World Report, highlighted new research from the University of Cincinnati's Alberto Espay.
Espay, MD, presented research at the American Academy of Neurology annual meeting that found an extended-release formulation of a Parkinson's drug could lead to more time where patients' symptoms are well managed.
Three doses of the new drug, called IPX203, was found to work slightly better at providing better "on time," or time where the medication is working and symptoms are lessened, compared to five doses of the standard formulation.
"If our brains aren’t making enough levodopa, then we have less of the dopamine that we need for movement and emotional regulation,” Espay told U.S. News. “Levodopa is to Parkinson’s what insulin is to diabetes. It’s actually replenishing something that the brain makes, but in these patients is making a little less than they need.
“This might well be used with five doses a day, and then this will be a marked improvement,” Espay continued. “Most patients really don't mind. What they're worried about is not how frequently they are taking it, but how much ‘off time’ they still may have. They don't want to have ‘off time’ regardless of how many times it takes for them to dose themselves.”
Read the U.S. News & World Report story, originally published on HealthDay.
Read additional coverage of the research on Neurology Live and MedicalResearch.com.
Espay also presented research on a subcutaneous delivery system for levodopa-carbidopa to treat Parkinson's at the conference.
Read the MedPage Today article on the research.
Read Neurology Live coverage of the research.
Featured photo at top of 3-D illustration of a dopamine molecule. Photo/Dr_Microbe/iStock.
Related Stories
CCM welcomes new film and media scoring faculty member J.R. Paredes
May 20, 2026
UC College-Conservatory of Music Dean Pete Jutras has announced the appointment of J.R. Paredes as CCM's new Assistant Professor of Film and Media Scoring. His faculty appointment officially begins on Aug. 15, 2026. Paredes is a composer, music producer and audio post-production specialist whose work spans film, television and commercial music. His credits include original scores for feature films and series distributed on platforms such as Apple TV+ and Prime Video, as well as extensive work in sound design and mixing for film and media.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.